
Opinion|Videos|April 4, 2025
Payer and Reimbursement Considerations for Bispecific Therapies
Experts discuss how payer and reimbursement considerations affect access to bispecific therapies in different practice settings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do payer and reimbursement considerations affect access to bispecific therapies in different practice settings?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Navigating Costs and Logistics of Cellular Therapies, ADCs, and Novel Diagnostics in Cancer Care
3
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
4
Team-Based Precision Oncology: Advancing Value and Access in Cancer Care
5















































